Drive demand, reduce screening costs, and increase participation in new trials with Kitsa’s AI-powered clinical trial solutions.
Clinical Research Organizations (CROs) often face high screening costs, limited trial participation, and low sponsor visibility. Standard processes and conventional clinical trial software slow recruitment and risk lost revenue. AI-powered clinical trial solutions streamline patient screening, accelerate enrollment, and connect sites with sponsors, boosting efficiency, revenue, and trial success.
Learn How Clinical Trial Recruitment Strategies Help Unlock New Revenue Channels
Low sponsor awareness limits trial participation
High administrative and screening costs reduce profitability
Limited referral networks restrict access to new patients
Difficulty managing unstructured data slows trial participation
Manual business development drains time and resources
Limited matching: Sites often miss Pharma opportunities
High cost: Solutions charge $20K+ with minimal gain
Manual networking: Access depends on personal connections
Inefficient referrals: Sharing patients across sites is slow
Opaque ROI: Revenue impact is hard to track
Kitsa leverages AI-powered clinical trial solutions to drive business impact for clinical research organizations by connecting sites to sponsors, automating referrals, and reducing manual costs.
Earn $1M–$4M more annually
Recruit patients faster with AI screening
Save weeks of manual pre-screening effort
Increase trial participation and site visibility
Access new trials via Kitsa marketplace
Kitsa is an AI-powered clinical trial solutions platform and marketplace for clinical research organizations, hospitals, and independent research sites. We help sites increase revenue, gain visibility with Pharma sponsors, reduce administrative costs, and recruit patients faster through AI-based matching, explainable insights, and secure referral networks.
"Kitsa transformed our patient recruitment model. We saw immediate multi-
million-dollar revenue potential and dramatically cut screening failures."
- Clinical Research Philadelphia
